[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004035823A3 - Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases Download PDF

Info

Publication number
WO2004035823A3
WO2004035823A3 PCT/EP2003/011478 EP0311478W WO2004035823A3 WO 2004035823 A3 WO2004035823 A3 WO 2004035823A3 EP 0311478 W EP0311478 W EP 0311478W WO 2004035823 A3 WO2004035823 A3 WO 2004035823A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
gene
neurodegenerative diseases
adenylytransferase
nmnat
Prior art date
Application number
PCT/EP2003/011478
Other languages
French (fr)
Other versions
WO2004035823A2 (en
Inventor
Der Kammer Heinz Von
Johannes Pohlner
Original Assignee
Evotec Neurosciences Gmbh
Der Kammer Heinz Von
Johannes Pohlner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh, Der Kammer Heinz Von, Johannes Pohlner filed Critical Evotec Neurosciences Gmbh
Priority to EP03785626A priority Critical patent/EP1552310A2/en
Priority to AU2003294696A priority patent/AU2003294696A1/en
Publication of WO2004035823A2 publication Critical patent/WO2004035823A2/en
Publication of WO2004035823A3 publication Critical patent/WO2004035823A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses the differential expression of a gene coding for Ensadin-0625 in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the Ensadin-0625 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.
PCT/EP2003/011478 2002-10-17 2003-10-16 Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases WO2004035823A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03785626A EP1552310A2 (en) 2002-10-17 2003-10-16 Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
AU2003294696A AU2003294696A1 (en) 2002-10-17 2003-10-16 Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41872102P 2002-10-17 2002-10-17
EP02023272 2002-10-17
US60/418,721 2002-10-17
EP02023272.4 2002-10-17

Publications (2)

Publication Number Publication Date
WO2004035823A2 WO2004035823A2 (en) 2004-04-29
WO2004035823A3 true WO2004035823A3 (en) 2004-07-22

Family

ID=56290494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011478 WO2004035823A2 (en) 2002-10-17 2003-10-16 Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases

Country Status (3)

Country Link
EP (1) EP1552310A2 (en)
AU (1) AU2003294696A1 (en)
WO (1) WO2004035823A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0902147D0 (en) * 2009-02-10 2009-03-25 Babraham Inst NMNAT2 modulator
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055202A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055202A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] XP002243555, retrieved from EBI Database accession no. ABB15460 *
MACK T G A ET AL: "WALLERIAN DEGENERATION OF INJURED AXONS AND SYNAPSES IS DELAYED BY A UBE4B/NMNAT CHIMERIC GENE", NATURE NEUROSCIENCE, NATURE AMERICA, INC, US, vol. 4, no. 12, December 2001 (2001-12-01), pages 1199 - 1206, XP008017577, ISSN: 1097-6256 *
RAFFAELLI NADIA ET AL: "Identification of a novel human nicotinamide mononucleotide adenylyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 297, no. 4, 4 October 2002 (2002-10-04), October 4, 2002, pages 835 - 840, XP002243554, ISSN: 0006-291X *

Also Published As

Publication number Publication date
EP1552310A2 (en) 2005-07-13
WO2004035823A2 (en) 2004-04-29
AU2003294696A8 (en) 2004-05-04
AU2003294696A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2003087403A3 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
WO2004035823A3 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
WO2003100092A3 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
DE60235996D1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF F-BOX PROTEINS IN MORBUS ALZHEIMER AND RELATED NEURODEGENERATIVE ILLNESSES
WO2005085472A3 (en) Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
DE602006019582D1 (en) ADARB2 PROTEINS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEURODEGENERATIVE ILLNESSES
WO2003104811A3 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
WO2003069347A3 (en) Diagnostic and therapeutic use of caps
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2006008294A3 (en) Diagnostic and therapeutic use of slim3 for neurodegenerative diseases
WO2005071418A3 (en) Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases
WO2003073104A3 (en) Diagnostic and therapeutic use of ma onconeuronal antigens for neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003785626

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003785626

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP